APTT 593
Asian populations
  Chinese 471, 529, 1871
  Eastern ..... 1948(L)
  Thai 1803, 2315
Aspirin, PLT function and 4S:206, 67
AS.TEC204 1241
Atrial natriiuretic peptice 1717
Austria 703, 1468, 1775
Autoantibodies
  with alloantibodies ..... 813, 1332(L)
  IAT crossmatch 1290
  RBC 2189
Autoimmune hemolytic anemia 50, 1290, 1902
Autoimmune thrombocytopenia 499
Autoimmune thrombocytopenic purpura 2161
Autologous tissue oversight 194
Autologous transplantation 115, 2153
Avian influenza A 1080

B

Baboon PLTs 4S:206
BacT/ALERT culture system
  AABB PLT criteria ..... 1340(E)
  failure 1381, 1391
  time dependence 2044
Bacterial contamination. *See* Platelet contamination
Bacterial detection
  in asymptomatic donor 1816
  concentration effects 1381
  culture-based (*See* BacT/ALERT culture system; Blood culture systems)
  doubling sample volume 430
  in PLT concentrates ..... 192(E), 421
  proficiency testing 251
Bacterial inactivation. *See* Pathogen inactivation
Bar code technology 2S:120S, 1674
Bayer analyzer 1651
B-cell lymphomas 1447
BeadChip array 736
Beckman Coulter 1651
Behavioral science, donor recruitment/retention and 1999
Belgium 217
Benchmarking 2S:145, 1468
Bernard-Soulier syndrome 103
bHCG 788
Biofilms 1143
BioMérieux system 2044
Bleeding
  after HSCT 801
  in elective surgery 1468
  H12-PEG-polyAlb treatment 1254
  massive 2S:176
  nonsurgical bleeding diathesis ..... 4S:206, 1744(E)
Bleeding time, hypothermia and 4S:206
Blood bank
  education curriculum content proposal 1930
  sickle cell patient management 2089
Blood-borne infections. *See also* Transfusion-transmitted infections; *specific infections*
  influenza viremia 1071, 1080
  SFV 162
Blood center-hospital relationship
  blood inventory management 2S:190
  clinical interaction and services 2S:172
  in England and North Wales 2S:158
  hemovigilance 1937
  management 2S:157
  Pittsburgh centralized transfusion model 2S:164
  supply chain management 2S:197
  Sweden 2S:169
  in treating massively bleeding patients 2S:176
Blood centers. *See also* Blood center-hospital relationship
  Comprehensive Sickle Cell Centers 2089
  hospital satisfaction with 2S:109
  role in transfusion recipient care 2S:101, 104
Blood collection agencies 385, 729, 763
Blood component therapy. *See also* Cellular therapy products; *specific blood components*
  bar code labeling 1674
  blood data collection reports ..... 366(E)
Blood conservation algorithm 832
Blood culture systems
  automated, predicting improvement of 430
  BacT/ALERT (*See* BacT/ALERT culture system)
  comparisons 1125
  false-negative rates 1381
  time-dependence 2044
  two-bottle 1381
  zero tolerance ..... 1106(E)
Blood data collection reports ..... 366(E), 373(E)
BloodGen project 1S:40
Blood groups. *See also specific blood groups*
  antibodies 1S:85
  DNA typing 1S:10
  expression systems 1S:85
  genotyping 1S:40, 47, 64, 95
  PCR-SSP typing 1S:54
Blood industry 1733
Blood inventory management 2S:190
Blood loss. *See* Bleeding
Blood safety. *See* Safety
Blood salvage, postoperative ..... 362(E)
Blood supply
  access, poverty and ..... 1952(E)
  donation promotion strategies 1607
  impact of demographic changes 395
  for influenza pandemic 1071
  shortages ..... 760(E)
  in United States 385
Blood utilization
  changing clinician's transfusion practices 2S:132
  computer-assisted system review 2S:142
  in elective surgery 1468
  in Germany 2S:152
  optimizing through benchmarking 2S:145
  patterns in elderly 582
  reducing 2S:149
Blood volume calculation, for pediatric transfusion 212
Bone fractures 792
Bone marrow product quality control 266
Bone marrow transplantation, allogeneic 266, 2276
BPA bottle 1391
BPN bottle 1391
Bradykinin 410
Brazilians
  donors, HIV risk and antiretroviral drug resistance profiles 97, 608
  Kell blood group antigens ..... 1552(L)
  Knops blood group haplotypes 147
  newborns, platelet alloimmunization and NT 59
Buffy coats ..... 126, 1555(L)
Butane-1,4-diol cooling plates 2038
B^w-alleles 864

C

Cadaver blood ..... 555(E)
Calorimetry, of contaminated platelets 1643
Canadia Blood Services
  anti-HBc testing 1809
  bacterial detection in PLTs 421
  consensus development ..... 2176(E)
  IVIG usage 2072
  predonation screening ..... 949(L), 1595, 1794
  suspected TT-HCV 1534
  TTI residial risk 316

Cancer
allogenic RBC transfusions ... 1691
lymphomas ... 499, 1447
Candida albicans ... 1405, 1643
Cardiac surgery ... 8, 1739(L), 2081
Cardiomyocyte-like cells ... 280
Cardioprotection ... 341
Caspase activation ... 1212
Catheter-related thrombosis ... 1837
CBF/NF-Y ... 23230
CD34+ ... 817, 2153
CD44 antigens ... 1306
CD20+ B-cell NHL ... 1447
CD34+ cells
collection ... 1230, 1851, 2207
content in UBC units for cryopreservation ... 552(L)
selection ... 2134
yield prediction ... 824
CD133+ cells ... 280
CD4 count ... 1710
CD11+c precursor dendritic cells ... 1241
CD47 expression ... 1725
CD44 gene ... 1306
CD14+ monocytes ... 1241, 2297
CD123+ precursor dendritic cells ... 1241
CD3 T-cell depletion ... 2134
CD8+ T cells, CMV-specific ... 2143
Cell culture technique ... 1426, 1436
Cell-Dyn 4000 ... 1651
Cellular therapy products
bar code labeling ... 1674
HHV-8 screening ... 1550(L)
implementation plan ... 1312
radiofrequency identification ... 2S:125S, 763, 946(L)
regulation of MHC expression ... 18
terminology and labeling standards ... 1319
CFU-GM ... 817
Chagas disease ... 90, 540
Chemiluminescence assays ... 1686
Chemokines ... 154
Chemotaxis ... 1395
Chemotherapy-based PBPC mobilization ... 629, 1447, 2153
Children. *See* Pediatric patients
Chimerism ... 1691
Chinese population ... 471, 529, 1871
C1-inhibitor deficiency ... 1028
Citrate anticoagulant system ... 2233
Classification, acute transfusion reaction ... 621
Clinical trials
design and reporting ... 2(E)
intention-to-treat principle ... 573, 1946(L)
randomization in ... 1753
treatment allocation ... 2187
CLL ... 361
CMV-specific cytotoxic T cells ... 2143
Coagulation factors. *See also specific coagulation factors*
in apheresis and leukodepleted WB-plasma ... 460
in irradiated FFP ... 1658
storage-generated microparticles ... 1880
warm storage of WB ... 2050
Coagulopathies ... 748(L), 749(L)
Cobas MPX test ... 1783
COBE Spectra plateletpheresis device ... 1241, 1943(L)
Cohort studies ... 1115
Cold agglutinins ... 361, 499
Compliance ... 1919, 2169(L)
Complications. *See* Adverse events
Compocool ... 2038
CompoCool-WB ... 2038
Composol AS ... 955
Comprehensive Sickle Cell Centers ... 2089
Computer-assisted systems
for blood utilization review ... 2S:142
for physician order entry ... 228
for self-interviews ... 1595
COM.TEC cell separator ... 824, 987, 2297
Confounder variable hypothesis ... 1945(L)
Congenital haptoglobin deficiency ... 2315
Consensus development ... 2176(E)
CONSORT guidelines ... 2(E)
Consortium for Blood Group Genes ... 1S:98
Controlled-rate freezing ... 935, 2202
Cord blood
for autologous RBC transfusion ... 1481
CD133+ cells ... 280
HSC recovery ... 1550(L)
transplant tolerance ... 272
Coronary artery bypass graft ... 1468
Cost, iron chelation therapy noncompliance ... 1919
Cost-effectiveness, of iron chelation therapy ... 1751(E), 1820
CPP ... 120
CRAM ... 1621
Creutzfeldt-Jacob disease, variant ... 1418, 2025, 2223
Cromer blood group system ... 1621
Crossmatch, IAT ... 1290
Cross-reactivity ... 723
CROV ... 1621
Cryopreservation ... 935, 1033, 2202
CTCLAG ... 1312
CTLs ... 256, 2143
Cultural values ... 402
Cyclophosphamide ... 2153
Cytokines ... 126, 154, 1691
Cytomegalovirus ... 1955(E), 1972

D

D alleles, weak ... 1350, 1616
D antigen ... 1S:17, 1616, 2197
DAT ... 697
Dce haplotype ... 486
Death
early, in AML ... 1843
intrauterine ... 911
TA-GVHD ... 1405
transplant-related ... 1494
DeBakey roller pump ... 953
Decay-accelerating factor ... 1621
Deferiprone ... 1919
Deferoxamine ... 1919
Deferrals, donor ... 1514, 1990
Deglycerolization ... 680, 2242
Delayed hemolytic transfusion reactions ... 1494
Deletions
genomic ... 852
haptoglobin-gene ... 1948(L)
RHD gene ... 1552(L)
DEL phenotype ... 1552(L)
DEL variant ... 852
Demographics, donor ... 395, 1862, 1871
Dendritic cells ... 256, 272, 1241, 2290
Denmark ... 2017
Desferrioxamine ... 1751(E)
DHPLC analysis ... 858
Diabetes mellitus, alloimmunization risk ... 2066
Differential in-gel electrophoresis ... 1221
Dimetyl sulfoxide-resistant filter, for cryopreservation ... 1033
Disulfide compounds ... 290
DMSO ... 1268, 2202
DNA analysis
Dombrock blood group ... 1356
Duffy blood group ... 1S:28
high-throughput ... 736
Kell blood group ... 1S:32
Kidd blood group ... 1S:23
Kx blood group ... 1S:32
limitations ... 1S:10

novel variations 1369
parvovirus B19 1756
QA for reagent RBCs 1S:73
RBC antigen phenotype 1S:60
Rh blood group system ..... 1S:17, 1337(E)
DOB allele 1356
Documentation 568, 763
Dombrock blood group 1356
Donath-Landsteiner antibody 1902
Donation. *See also* Donors
autologous 832
employer-organized 1871
improving 402
intention 1006
National Marrow Donor Program ..... 1101(L)
opinions 729
pediatric elective surgery 1503
repeated 1607, 1862
symptoms 995, 2217
vasovagal reactions 1524
Donation archives ..... 1110(E), 1172
Donor lymphocyte chimerism 781
Donor-recipient repositories ..... 1110(E)
Donors
altruism 1862, 1999
asymptomatic, detection of bacterial contamination in 1816
attention 1595
Brazilian, HIV risk in 608
Chinese, residual risk for HCV and HIV 2011
cytomegalovirus DNA in 1972
D- ..... 1337(E)
deferrals 890, 895, 1514
exclusionary factors 1180
female, TRALI risk and ..... 559(E), 563(E)
first-time 1514, 1524, 1862
French, anti-LCMV in ..... 172(L)
genotyping operational issues 1S:69
improving health profile 2017
intention to redonate 1006
male 599
mass-scale genotyping 1S:40
Pakistani 74
parvovirus B19 DNA levels 1756
platelet counts 1601
potential U.S. pool 1180
promotion strategies for 1607
rare blood ..... 754(E)
RBC antigen phenotype by DNA analysis 1S:60
recruitment 1999
repeat 1514, 1862
retention of 995, 1999
sickle trait 2233
Swedish 80
symptoms 995, 2217
TRALI, management of 1118
vasovagal reactions 1524
weak D+ ..... 1337(E)
whole-blood 67, 890, 895
Double-RBC collection 995, 1002, 2025
DPG 2050
DRB3+0101 2322
Drug-induced immune hemolytic anemia 697
Drugs. *See specific drugs*
Duffy blood group 28
DNA analysis 1S:28
PCR-SSP 1S:54
transfusion-induced autoantibodies 2189

E

East Asian population ..... 1948(L)
eBDS 2044
E blood group 2126
Education 228
Elderly blood use patterns 582
Elective surgery 1468, 1503
ELISA 90, 1630
Elutra cell separator 2290
Emerging Infections Network 1206
Emily Cooley Award Lecture 2006 1733
Endothelial-like cells 280
England, blood center-hospital relationship 2S:158
Engraftment prediction 817
Equilibrium freezing 935
Erythrocytapheresis 788, 1002
Escherichia coli 1643, 1896
ESHAP 1447
Eucaryote recombinant Lu^b 1630
Europe
blood supply 395
travel deferrals 2025
Evidence-based medicine 1963
Exon 8 deletion 852
Extracorporeal blood volume 1717
Extracorporeal bypass 4S:206

F

FCγ receptor-mediated phagocytosis 290
FDA
plateletpheresis guidance 1601
role in immunohematology 1S:3
tissue recall 927
Febrile nonhemolytic transfusion reactions 1089
Females, alloimmunization risk 2066
Ferritin 1820
Fetal bovine serum 1436
Fetal Cell Count kit 1281
Fetomaternal alloimmune thrombocytopenia 901, 1296, 1510
Fetomaternal hemorrhage 1281
Fetus
blood group genotyping 1S:64
PLTs 1363
RBCs in maternal blood 1281
FFP
ADAMTS13 in 120
compliance with transfusion guidelines ..... 2169(L)
irradiated, coagulation system in 1658
for mild coagulation abnormalities ..... 748(L)
proactive administration for AAA 593
Fibrinogen γ-chain dodecapeptide 1254
Fibrinolytic system, in irradiated FFP 1658
Filgrastim 969
Flow cytometry 478, 1281, 1350
Fluorescence-activated cell sorting 1281
Follicular lymphoma 499
France, anesthesia-related deaths in 2S:184
Freezing with nonpenetrating polymers 935
Fresnius COM.TEC cell separator. *See* COM.TEC cell separator
FUT2 alleles, novel 1369
FUT2 gene 1369
FV 460
FVa 1880
FVII ..... 8, 749(L)
FVIII 460

G

Galactosylation, of PLTs 442
Gamma irradiation 653, 1658
G-CSF 41, 969, 2153, 2207
Gel antigen-specific assay 1363
Genotyping
ABO 2110
blood group typing using PCR-SSP 1S:54
Duffy blood group 1S:28
fetal 2126
HBV 1794
HPA 1637

mass-scale 1S:40
Germany
blood group genotyping 1S:47
blood utilization 2S:152
parvovirus B19 donor screening 1775
Glycolipids 876
Glycolysis 1666
Glycoprotein IIIa 2260
Glycoprotein VI 2057
Glycosyltransferase 864
GM-CSF 2153
Good manufacturing practices 520, 1588
Grandparentage analyses 335
Granulocytes 969, 1268
Granulocyte transfusions 2185
Gravity separation, of RBCs 2271
GVHD
lower incidence after CB transplant 272
pediatric 2276
transfusion-associated, prevention of ..... 173(L)

H

Half-sibship 515
Haplotypes, X-chromosome 1050
Haptoglobin gene ..... 1948(L), 2315
HBOC-201 ..... 723, 2098
HBsAg 1162, 1197, 1809
HBV
antigenemia 1162
duration in donors 1162
HBc donor screening 1794, 1809
multiplex NAT 1783, 1803
in Pakistan 74
residual risk 316, 529
HCV
in children 615
interassay correlation 1686
multiplex NAT 1783, 1803
residual risk 316, 529
residual risk for Chinese donors 2011
risk factors among Israeli donors 1189
sequence analysis confirmation ..... 1102(L)
suspected transfusion-transmitted 1534
Health-care issues 1733
Heart valve replacement 341
Hemagglutination inhibition test 1630
Hematocrit
bleeding time and 4S:206
in blood volume calculation for children 212
PLT transfusion trigger 4S:206
seasonal variation 890
Hematologic recovery rate 817
Hematology analyzers 1651
Hematopoietic progenitor cells
autologous blood
postchemotherapy 629
autologous postchemotherapy 629
bacterial contamination
culture-positive 636
infusion
autologous blood
adverse events 1268
recovery from cord blood ..... 1550(L)
sterility testing 636
Hematopoietic progenitor cell transplant recipients
of rare blood ..... 754(E)
Hematopoietic stem cell transplant 2305
Hemicolectomy 1468
Hemodilution, acute normovolemic 341
Hemodynamics, during plasmapheresis 1717
Hemoglobin
bovine 723
fetal 1281
neonatal 1858
sickle cell 2233
Hemoglobin-based oxygen carriers 2098
Hemoglobinopathies ..... 1552(L)
Hemolysis
after PLT transfusion 1412
childhood AIHA 50
cord RBC units 1481
Hemolytic anemia
drug-induced 697
fetal 911
Hemolytic disease of newborn 2126
Hemophilia 8
Hemorrhage
controlled, HBOC use in 2098
intracranial 8, 901
Hemostasis 4S:206, 374
Hepatitis B core antigen 1809
Hereditary angiedema 1028
Herpesvirus 8 ..... 1550(L)
HEX 2098
Hip replacement 379, 832, 1468
HIV
Brazilian donors and 97, 608
multiplex NAT 1783, 1803
residual risk 316, 529, 2011
resistance in recipient ..... 1328(L)
TTP 1710
HLA-A2-Ig-based artificial APCs 2143
HLA/Cw typing 2322
HLA-DR antibodies 154
HLAs
alloimmune response 2322
Class II 154
conditional silencing 18
production after PBPCT 326
sensitization 374
typing 1405
H5N1 1080
HNA-reactive neutrophil antibodies 478
Hodgkin's disease 2207
Hollow-fiber filtration system 2271
Hospitals. *See also* Blood center-hospital relationship
Belgian 217
concentration of transfusion resources 217
relationship with blood center 2S:106, 109, 114, 117
revenue, blood and 2S:114
satisfaction with blood center 2S:109
tertiary-care, PLT transfusion triggers 206
tissue oversight ..... 185(E)
tissue recall management plan 927
HPA-1a antibody 901, 1296
HPA-1 alloantibodies 1363
HPA-5b antibodies 901
HPA-15b antibodies 901
HPA-13bw 1510
HPA-immunized pregnancy 901
HPAs 1637
HPA-5 system 59
HPBPCT 1494
HLA antibody production 326
HPC grafts
DMSO-reduced 1268
HPC mobilization
chemotherapy-based 629, 1447, 2153
HPCs
in optimizing PBPC collection 1851
HPCT 781
HPCT, allogeneic 781
Hp^{del} ..... 1948(L)
Hp^{del} 2315
H12-PEG-polyAlb 1254

HSCT
bleeding complications ... 801
outcome ... 1700
HTLV, residual risk ... 316
Human development, blood supply access and ... 1952(E)
Human platelet lysate ... 1436
Human platlete antigen-1a ... 2322
HVN1 influenza ... 452
Hydroxyethyl starch ... 1329(L)
Hydroxyurea ... 1830
Hypercoagulability ... 792
Hyperleukocytosis ... 1843
Hypersplenism ... 41
Hypocalcemia ... 1837
Hypotension
leukoreducted PLTs and ... 410
from pediatric apheresis ... 1837
pediatric autotransfusion ... 1503
vasoactive mediators and ... 369(E)
Hypothermia ... 4S:206

I

Identification, patient ... 2S:125S, 1674
Idiopathic thrombocytopenic purpura ... 2072
IgA1 ... 306
IgG ... 306, 723, 1212
IgM ... 499
IgM B19 antibody ... 1756
Immigrant blood donors ... 1189
Immune deficiency ... 2072
Immune hemolytic anemia, drug-induced ... 697
Immune response, tumor-specific ... 256
Immunization ... 256
Immunocompetence ... 1405, 1455
Immunoglobulin-like transcript 1 ... 1395
Immunohematology
DNA-based technology ... 1S:1
FDA role in ... 1S:3
molecular methods ... 1S:10
phage display-based molecular methods proteins ... 1S:89
Immunomodulation, RBC transfusion ... 1691
Immunoselection ... 280
Immunotherapy ... 520
Impact-R analysis ... 103
Impedance cardiography ... 1719
Indian blood group system ... 1306
Indirect antiglobulin test crossmatch ... 1290
Infants ... 8
Infections, in thalassemia intermedia ... 792
Influenza ... 452, 1071, 1080
Influenza virus
pandemic ... 1071
Informed consent ... 557(E)
Integrin antibodies ... 499
Intention-to-treat principle ... 573, 1946(L)
INTERCEPT ... 434, 666
Interferons ... 1691
Interleukins ... 1691
Intracranial hemorrhage ... 8, 901
Intrauterine death ... 911
Intrauterine transfusion ... 901, 1488
Intravenous drug users ... 1189
Investigation
TRALI ... 1118, 1679
transfusion-transmitted HCV ... 1534
In vitro diagnostic products ... 1S:3
Iron, intravenous ... 1905
Iron chelation therapy ... 1751(E), 1820, 1919
Iron overload ... 1820
ISBT 128 ... 1312, 1674
ISBT/ICSH international workshops ... 1S:95
Israeli donors ... 1189
IVIG ... 901, 2072, 2250

J

Japanese Red Cross ... 1197
Japanese repositories ... 1105
JCAHO standards ... 194
JK^a ... 1S:23
JK^b ... 1S:23
JMH blood group system ... 133

K

K4500 analyzer ... 1651
KATOIII cells ... 842
K562 cell panel ... 478
K562 cells ... 256
Kell blood group
antigens, high-prevalence ... 1552(L)
autoantibodies ... 2189
DNA analysis ... 1S:32
fetal genotyping ... 2126
KELnull and KELel ... 703
PCR-SSP ... 1S:54
Kidd blood group
autoantibodies, transfusion-induced ... 2189
DNA analysis ... 1S:23
renal allograft rejection ... 28
Kidney failiure ... 511
Kinins ... 410
KIRs ... 2322
Klebsiella pneumoniae ... 1336, 1896
Knee replacement ... 379, 1468
Knops blood group system ... 147
KODE technology ... 876
Kx blood group ... 1S:32

L

Labeling
bar code technology ... 2S:120S, 1674
error reduction ... 771
radiofrequency technology ... 2S:125, 763, 946(L)
standards for cellular therapy products ... 1319
Leclercia adencarboxylata ... 1816
Lectin binding ... 966
Lenograstim ... 969
Lentiviral-based vector systems ... 18
Leukapheresis
in AML ... 1843
CD34+ cell yield ... 824
good manufacturing practices ... 1588
monocyte enrichment ... 2290
PBPC mobilization and ... 2153
precursor dendritic cells ... 1241
Leukemia ... 361, 1843, 2207
Leukoencephalitis, acute hemorrhagic ... 981
Leukoreduced RBC transfusions
postthaw storage ... 2242
in surgical patients ... 573, 1946(L)
Leukoreduction
COM.TEC cell separator ... 824, 987, 2297
hypotension ... 410
postoperative infection and ... 1945(L)
universal prestorage ... 1455
whole-blood from sickle trait donors ... 2233
whole-blood plasma ... 460
Leukoreduction system chambers ... 1042, 1943(L)
Likelihood ratios ... 515
Lipid raft-associated proteins ... 1212
Liver disease ... 8, 792
Locked nucleic acid ... 2126
Lookback study
HBV ... 1197
HCV ... 615
Lutheran blood group system ... 492, 1630
LW antigen ... 1755
Lymphocyte subpopulation phenotyping ... 1691

Lymphocytic choriomeningitis virus ..... 172(L)
Lymphoma 499, 1447

M

Magnetic cell sorting program 2134
MAIEA assay 1306
MAIPA assay 1363
MALDI-TOF MS ..... 1099(L)
Male genetic transmission 918
McLeod phenotype 299
Medical device companies ..... 1098(L)
MEIA assay 1686
Melphalan 115
Mesenchymal stromal cell propagation 1426, 1436
Meta-analysis
  intravenous iron 1905
  of leukoreduced blood transfusions ..... 573, 1946(L)
  of PLT dose 464
Metabolic problems, in thalassemia intermedia 792
MHC expression 18
Microbial detection methods 1643
Microbiologic screening test, false-reactive results 80
Microcalorimetry 1643
Microchimerism 1691
Microparticles, storage-generated 1880
Minor histocompatibility antigens 28
Minority blood donation improvement 402
Misfolded protein diagnostic assay 1418
Misssense mutations 1014, 1306
Mithramycin A 842
Mitomycin C-associated thrombotic microangiopathy 1263
Mobilization
  CD34 cells 1230
  rituximab-ESHAP regimen 1447
Molecular assays
  guidelines/proficiency testing 1S:79
  in immunohematology 1S:10
Monocyte enrichment 2290
Mononuclear cells 1042, 1234, 2161
Mortality. *See* Death
Mouse model 2305
M-sol additive solution 960
Multicenter studies 644, 2011, 2081
Multiple myeloma 115, 2207
Murine model 41, 1418, 1725
Muscle tension technique 2217
Mutations
  B-related subgroup 864
  inactivating 492
  XK 299
Myeloma-associated renal failure 511

N

NAT
  anti-HBc 1794
  automated multiplex 1783
  false-reactive results 80
  HBV 1162
  HCV ..... 1102(L)
  minipooled ..... 883, 1102(L), 1197, 1775
  multiplex 1803, 2011
  parvovirus B19 1775
  viral infection residual risk 529
National Blood Collection and Utilization Survey ..... 366(E)
National Marrow Donor Program ..... 1101(L)
Neonatal alloimmune thrombocytopenia ..... 6(E), 1363, 1488, 1510
Neonatal anemia 1S:10
Neonatal thrombocytopenia 59
Neuroacanthocytosis 299
Neutropenia 2185
Neutrophil chemotaxis 1395
Neutrophil-specific antibodies 478, 545, 559
Nitric oxide 4S:206
NK cell processing 520
Norway 1674
NovoSeven, "off-label" usage 8
NSAIDs 67, 697
Nucleated RBC quantification 266
Null alleles 1S:73
Null phenotype 492

O

Observational studies 1115
Occupational exposure predonation screening questions ..... 949(L)
Onyx analyzer 1651
Open-heart surgery 953
OrbiSac system ..... 126, 1555(L)
Orientia tsutsugamushi 240
Orthostatic hypotension 1524

P

PAGGS-M 1481
PAR4 ..... 1054, 1745(E)
Paracetamol 67
Parentage analysis 1050, 1276
Paroxysmal cold hemoglobinuria 1902
PARV4 1054
PARV5 1054
Parvovirus B19
  blood transfusion and ..... 1745(E)
  DNA 883, 1756
  donor screening 1775
  inactivation 1062, 1765
PAS-IIIM 1889
Passenger lymphocytes, donor-derived 1488
Passive transfusion 788
Pasteurella multiocida bacteremia 1984
Paternal lineage analysis 918
Paternity testing
  exclusionary power 335
  single-parent ..... 947(L)
Pathogen inactivation ..... 2180(E)
  efficacy ..... 1106(E), 1125, 1896
  parvovirus B19 1765
Pathogen reduction technology. *See also* Pathogen inactivation; Photochemical treatment
  PCT with amotasalen and UVA 434
  riboflavin and light 240
Pathology residency programs 1930
PBMNCs 1691
PBPCs
  collection 1230, 1234, 1851
  cryopreservation 2202
  mobilization 2153
PBPC transplantation
  alloimmunization risk 2066
  CD3 T-cell depletion 2134
  engraftment prediction 817
PCR
  allele-specific polymorphism strategy 2110
  CMV DNA 1972
  cytomegalovirus DNA ..... 1955(E)
  parvovirus B19 DNA 1756, 1775
  RHD typing 1350
PCR-ASP analysis 2110
PCR-RFLP 1637
PCR-SSP blood group typing 1S:54, 1637
Pediatric patients
  apheresis complications 1837
  autotransfusion for elective surgery 1503
  blood volume calcuation 212
  GVHD 2276
  HCV in 615
  hemolysis after PLT transfusion 1412
  PBPC cryopreservation 2202
  rFVIIa usage 8

Pegfilgrastim 969
pH
  parvovirus B19 inactivation 1765
  PLT 1666, 1889
Phage display-based molecular methods proteins 1S:89
Phagocytosis
  FCγ receptor-mediated 290, 2250
  PLT 442, 2161
  RBC 2161
Pharmaceutical industry ..... 1098(L)
Phosphatase 2161
Phosphate-buffered saline 2242
Photochemical treatment 2276
  with amotosalen and UVA 666
  parvovirus B19 inactivation 1062
  PLT quality 653
  PLTs in plasma 1896
Photophoresis 2276
Physician transfusion practices 2S:132
Pittsburgh centralized transfusion model 2S:164
Placental blood 2271
Plasma-clotting proteins 4S:206
Plasma exchange, therapeutic. *See* Therapeutic plasma exchange
Plasmapheresis
  ANP in 1717
  light-chain removal 511
  seasonal variation in HCT 890, 895
Plasma products
  ADAMTS13 in 120
  cytomegalovirus DNA in 1972
  H5N1 influenza virus and 452
  parvovirus detection in 1054
  rickettsial inactivation 240
Platelet activation
  cytokine release and 126
  during storage ..... 1555(L), 2057
Platelet additive solutions 955, 960, 1889
Platelet alloimmunization 59
Platelet cold agglutinins 499
Platelet concentrates
  bacterial contaminated (*See* Platelet contamination)
  bacterial detection (*See* Bacterial detection)
  bacterial infections associated with 1206
  bacterial testing ..... 192(E)
  buffy-coated ..... 666, 1099(L)
  concentrates (*See* Platelet concentrates)
  cryopreserved 4S:206
  donor painkiller usage and 67
  fresh 4S:206
  frozen 4S:206
  gamma-irradiated 653
  glycoprotein IIIa 2260
  hyperconcentrated 1488
  leukoreduced 666, 987
  for nonsurgical bleeding diathesis 4S:206
  pathogen inactivation 240
  pH 1666, 1889
  photochemical treatment 434
  platelet activation and cytokine release 126
  posttransfusion purpura 1455
  preserved 4S:206
  prestorage pooling 1154
  proactive administration for AAA 593
  quality of 4S:206, 653
  radiolabeling procedure ..... 946(L)
  recovery 2305
  refractoriness 374
  screening ..... 1106(E)
  single-donor ..... 192(E)
  storage (*See* Platelet storage)
  survival/function, in Bernard-Soulier syndrome 103
  transport 1666
  trehalose-stablized freeze-dried outdated 672
  utilization 201
  in vivo recovery 1540
  whole-blood-derived ..... 192(E), 1896
Platelet contamination
  AABB criteria ..... 1340(E)
  abnormal appearance 1961
  collection method comparisons 644
  detection of 1643
  detection proficiency testing 251
  gross 1336
  Leclercia adecarboxylata 1816
  low levels of bacteria 1125
  parvovirus B19 inactivation 1062
  Pasteurella multocida 1984
  progress assessment ..... 1340(E)
  Staphylococcus epidermidis biofilms 1143
  Staphylococcus lugdunensis 1390
  transfusion-transmitted infections 1206
Platelet count
  automated 1651
  bleeding time and 4S:206
  frequent plateletpheresis and 1601
  G-CSF-induced thrombocytopenia and hypersplenomegaly 41
  low 1700
  transfusion trigger 4S:206, 201, 206
  as transfusion trigger 801
Platelet disorders, qualitative 8
Platelet factor 4 ..... 1099(L)
Platelet function
  aspirin 4S:206, 67
  bleeding time and 4S:206
  in extracorporeal bypass, skin temperature and 4S:206
Platelet pH 1666
Platelet phagocytosis 2161
Plateletpheresis
  asymptomatic donors 1816, 1984
  bacterial detection 421, 1134, 1816
  with COM.TEC cell separator 987
  frequent 1601
  resident cell content 1042
  safety profile 1002
Platelet proteins, alterations during storage 1221
Platelets
  aggregation, painkillers and 67
  baboon 4S:206
  coated 2057
Platelet storage
  activation during ..... 1555(L)
  agonist-induced responses 653
  alterations during 1221
  glycoprotein III a 2260
  hemostatic potential and 2057
  interuption of agitation 955
  lesions ..... 1099(L)
  long-term refrigeration 442
  microparticles 1880
  in M-sol 960
  pH 1889
  prestorage pooling 1154
  seven-day 666
  Staphylococcus epidermidis biofilms 1143
  without agitation 955
Platelet substitutes 1254
Platelet transfusions
  blood data collection reports ..... 366(E)
  hemolysis after 1412
  indications 201
  prophylactic ..... 188(E), 801, 1700
  refractoriness 326
  survival 4S:206
  trigger 4S:206
  triggers ..... 188(E), 201, 206, 1700
  in United States 385

Polymorphisms
allele-specific PCR strategy ... 2110
Dombrock blood group system ... 1356
nonexofacial ... 2189
SNPs ... 147, 1337(E), 1369
Polyneuropathy, demyelinating ... 2072
Polyolefin bags ... 1241
Postoperative blood salvage ... 362(E)
Postoperative infections ... 573, 1945(L)
Predonation screening
in Canadia ... 949(L), 1595, 1794
Chagas antibody ELISA ... 90
DNA typing ... 1S:10
false-reactive results ... 80
high-throughput DNA analysis ... 736
medication usage ... 67
multiplex NAT ... 1803
parvovirus B19 ... 1775
questions ... 949(L)
RHD typing ... 1350
uniform donor history questionnaire ... 1595, 1990
Pregnancy
anti-Fy^a alloimmunization in ... 1858
HPA-immunized ... 901, 1296
Pregnancy test, posttransfusion false-positive ... 788
Premedications ... 1089
Prenatal laboratory evaluation ... 2170(L)
Pretransfusion bedside check ... 771
Primate model ... 162, 949(L), 2223
Prion proteins ... 1419, 2223
Procaryote recombinant Lu^b ... 1630
PROCLEIX ULTRIO assay ... 1783
Professionalism ... 1733
Proficiency tests ... 1S:79, 95
Progenitor cell automated collection ... 1234
Prognosis ... 2207
Prophylaxis
platelet transfusions ... 188(E), 801, 1700
RBC exchange ... 1494
Propionibacterium acnes ... 1643
Prospective cohort studies ... 1115
Protein A immunoadsoption therapy ... 1263
Protein C, activated ... 1880
Proteomic profiling ... 1221
PRP, abnormal appearance ... 1961
PrP^{TSE} ... 1418
Pseudoxanthoma elasticum ... 792
Public health notification ... 1534
Pulmonary hypertension ... 792
Pulmonary reactions, neutrophil-specific antibodies and ... 545
Purpura
autoimmune thrombocytopenic ... 2161
posttransfusion ... 1455
PVC bags ... 1241

Q

Quality control ... 2S:137, 733, 1134

R

Radiofrequency identification technology ... 2S:125, 763, 946(L)
Random grandparents not excluded ... 335
Randomization, in clinical trials ... 1753
Randomized controlled trials, meta-analysis of PLT dose ... 464
Randomized crossover study, automated PBPC collection ... 1234
Rare blood ... 754(E), 781, 1630
Rat model ... 1254
RBC additive solutions ... 680, 2242, 2271
RBC alloimmunization ... 781, 1959(E)
RBC antibodies ... 781
RBC antigens
donor genotyping operational issues ... 1S:69
phenotypes ... 1S:60, 736, 1616
RBC autoantibodies ... 50, 2189
RBC collection
automated double ... 995
blood data collection reports ... 366(E)
safety profile ... 1002
RBC exchange, prophylactic ... 1494
RBC membranes
carbohydrate changes during storage ... 966
remodeling in storage ... 1212
synthetic glycolipid modifications ... 876
RBC phagocytosis ... 2161
RBCs
additive solutions ... 680
loss (*See* Bleeding)
from placental blood ... 2271
rare ... 754(E)
reagent for DNA analysis, QA of ... 1S:73
resuspension in AS-3 ... 680
rickettsial inactivation in ... 240
senescence ... 1725
storage ... 966
yield ... 2297
RBC transfusions
alloimmunization ... 2066
auto- and alloantibodies from ... 813
blood data collection reports ... 366(E)
D+, detection anti-D in D- in recipients ... 2197
in elective surgery ... 1468
HIV-RNA-positive/anti-HIV-negative donor ... 1328(L)
immunomodulary effects ... 1691
large-volume, in cardiac surgery ... 2081
leukoreduced ... 1691
for major spine surgery ... 1022
for nonsurgical bleeding diathesis ... 4S:206
triggers ... 4S:206
in United States ... 385
unmodified ... 1691
in vivo TGF-β1 induction ... 1395
RBC units, cord ... 1481
RBC volume calculation, for pediatric transfusion ... 212
Recombinant anti-D ... 306
Recombinant C1-inhibitor ... 1028
Recombinant Lu^b ... 1630
Recombinant proteins ... 1S:85
REDS-II Leukocyte Antibody Prevalence Study (LAPS) ... 563
Regulatory T cells ... 272
Renal failiure ... 511
Reporting, suspected transfusion-transmitted HCV ... 1534
Research questions ... 15
Retransfusion, of filtered shed blood ... 379
Retrospective analysis
cohort studies ... 1115
spine surgery transfusion practice ... 1022
rFVIIa ... 8
Rh(D) alloimmunication ... 1959(E)
Rh blood group system
anti-D in D+ individuals ... 1755
DNA genotyping ... 1S:17, 1337(E)
D variants ... 471
D variants in Chinese population ... 471
fetal genotyping ... 2126
genotyping ... 1S:47
PCR-SSP typing ... 1S:54
phenotypes ... 1S:60, 736, 1616
serologic typing ... 1S:17
transfusion mismatch ... 2197
RHCE gene ... 486
RHD gene
deletions ... 852, 1552(L)
DNA analysis ... 852
mosaicism/chimerism ... 715
novel alleles ... 858
quantitation ... 715
typing ... 1350

weak D 1616
RhD zygosity 715
Rh hemolytic disease 306
rHuEPO 832
Riboflavin and light, inactivation of blood products 240
Rickettsia inactivation 240
Rituximab 1902
Rituximab-ESHAP regimen 1447
RNA inhibition ..... 4(E)
RNA transfection 256
RT-PCR 715, 1637
RV-PBSC 824

S

SABM abstracts from 2006 Annual Meeting 351
Safety ..... 758(E)
of automated collection 1002
bar code labeling 1674
blood center-hospital relationship and 2S:106
blood supply access ..... 1952(E)
error prevention 1733
hemovigilance 1937
H5N1 influenza virus and 452
hydroxyurea in thalassemia major 1830
improving donor health profile 2017
intravenous iron therapy 1905
monitoring ..... 1110(E)
pathogen inactivation ..... 2180(E)
uniform donor history questionnaire 1990
weak D phenotypes and 1616
SAGM additive solution 2271
Saline-adenine glucose-mannitol 2242
Sampling, culture-based bacterial detection 2044
SCID 1540
Scottish National Blood Transfusion Service 1172
Seasonal variation, HCT 890, 895
Sema7A 133
Sepsis, residual risk 1134, 1381
Seroconversion, cytomegalovirus 1972
Serology testing
AIHA in childhood and 50
cytomegalovirus seroconversion 1972
drug-induced immune hemolytic anemia 697
D typing 1S:17, 1616, 1755
HBV 1162
Serum free light-chains 511
sFasL 1395
sHLA-I 1395
Short tandem repeats
autosomal 1276
half-sibships 515
X-linked 1050, 1276
shRNAs 18
Siblings 515
Sickle cell anemia 781
Sickle cell disease 1S:10, 2089
Sickle cell trait 2233
Simian foamy virus ..... 162, 949(L)
Single-nucleotide transitions 1014
Skin temperature 4S:206
SNPs ..... 147, 1337(E), 1369
Social science, donor recruitment/retention and 1999
Solid malignancy alloimmunization risk 2066
Southeast Asian population 2315
Spanish popuulation ..... 948(L)
Spectra apheresis machine 1234
Spine surgery 1022
Splenomegaly 41, 792
Staphylococcus aureus
detection 1643
inactivation 1896
Staphylococcus epidermidis
biofilms 1143
detection 1643
inactivation 1896
Staphylococcus lugdunensis 1390
Stem cell transplants 2207, 2305
Sterility testing, HPCs 636
Storage
extended, of frozen-thawed AS-5 RBCs 680
microparticles 1880
platelet (*See* Platelet storage)
RBC 687
RBC membrane remodeling 1212
short-term liquid 1241
Staphylococcus epidermidis biofilms 1143
whole-blood 2038, 2050
whole-blood plasma 460
Storage facilities 1105
Streptococcus sanguinis 1643
Structure-function studies 290
Sulfhydryl groups 290
Surgery
arthroplasty 379, 832, 1468
cardiac 2081
elderly, blood utilization patterns 582
elective 1468, 1503
leukoreduced transfusions for ..... 573, 1946(L)
open-heart 953
pediatric 1503
spinal 1022
tranfusion complications 2S:184
transfusion practice 1022
Sweden 2S:169, 80, 2017
Systematic reviews 1347

T

TACO ..... 171(L), 1118
TA-GVHD
in immunocompetent patients 1405
posttransfusion purpura 1455
prevention ..... 173(L)
Taiwanese population 1014
TaqMan PCR 1972
TaqScreen multiplex test 1783
T-cell depletion 2134
TCR analysis 1691
Temperature
bleeding time and 4S:206
clotting time and 4S:206
seasonal variation, HCT and 890
WB cooling plates 2038
whole-blood storage 2050
Terminology standards, for cellular therapy products 1319
TGF-β1 ..... 1395, 1481
Thai population 1803, 2315
Thalassemia intermedia 792
Thalassemia major 1830, 1919
Theory of Planned Behavior 1006
Therapeutic apheresis 1963
Therapeutic plasma exchange
for acute hemorrhagic leukoencephalitis 981
ADAMTS13 in 120
TTP-HUS outcome 107
Thrombin 2057
Thrombocytopenia
autoimmune 499
G-CSF-induced with hypersplenism 41
H12-PEG-polyAlb treatment 1254
nonsurgical bleeding diathesis ..... 4S:206, 1744(E)
prophylactic PLT transfusion 464, 1700
Thrombocytopenic purpura-hemolytic uremic syndrome. *See* TTP-HUS
Thromboelastography 2057, 2098
β-Thromboglobulin ..... 1099(L)
Thrombotic microangiopathy, mitomycin C-associated 1263
TIGRIS system 1783

Time dependence, culture-based bacterial detection 2044
Timersal 2250
Tissue recall management plan 927
T-lymphocytes
  cytotoxic 256, 2143
  posttransfusion purpura 1455
TNF-α 1481
Tolerance 272
Total hip arthroplasty 379, 832, 1468
Total knee arthroplasty 379, 1468
TRALI
  female donor risks ..... 559(E), 563(E)
  HLA Class II antibodies 154
  investigation and donor management 1118
  neutrophil-specific antibodies ..... 545, 559(E)
  policies/practices 1679
  risk reduction ..... 559(E), 563(E)
  surveillance 599
  TACO and ..... 171(L)
Transfusion chelation therapy 792
Transfusion costs 217
Transfusion medicine
  curriculum content proposal 1930
  hemovigilance 1937
  policies ..... 754(E), 781
Transfusion reactions
  acute, classification of 621
  documentation 568
  febrile nonhemolytic 1089
  residual risk 1134, 2011
  septic, residual risk 1134, 1381
Transfusions
  complications 2S:184
  computerized decision support interventions 228
  documentation 568
  inappropriate, reducing 228
  leukoreduced 573
  for massive bleeding 2S:176
  parvovirus and ..... 1745(E)
  pathologies requiring 217
  premedications 1089
  radiofrequency identification technology ..... 2S:125, 763, 946(L)
  for thalassemia intermedia 792
  vs. hydroxyurea in thalassemia major 1830
Transfusion services
  bedside error reduction 771
  blood shortages ..... 760(E)
  for influenza pandemic 1071
  role of ..... 185(E)
Transfusion-transmitted infections
  blood donation archive repository 1172
  detection methods ..... 1106(E)
  parvovirus B19 donor screening 1775
  prevention ..... 1125, 2180(E)
  prevention of cytomegalovirus ..... 1955(E)
  reporting/investigating 1534
  residual risk 316, 529, 2011
  risk from Brazilian donors 608
  Trypanosoma cruzi 540
Transport, PLT concentrate 1666
Trauma 8
Travel deferral 2025
Treatment allocation, in clinical trials 2187
Trehalose-stablized freeze-dried outdated platelets 672
Trima Accel platletpheresis device ..... 1042, 1488, 1943(L)
Trypanosoma cruzi
  antibody detection 90
  inactivation 434
  transfusion-acquired infection 540
TSE 1418, 2223
TTP, HIV-related 1710
TTP-HUS 107

U

Ultrarapid freezing 935
Umbilical cord blood. *See* Cord blood
Uncontrolled-rate freezing 2202
Uniform donor history questionnaire 1990
United States. *See also* American Red Cross
  blood collection and transfusion 385
  potential blood donor pool 1180
  TRALI policies/practices 1679
UVA with amotosalen. *See* Amotosalen with UVA

V

Vasoactive mediators ..... 369(E)
Vasovagal donor reactions 1524
vCJD. *See* Creutzfeldt-Jacob disease, variant
Viruses. *See specific viruses*
Vitrification 935
VWF 1710

W

Wales, blood center-hospital relationship 2S:158
Water drink, vasovagal donor reactions and 1524
WBC antibodies 599
WBC chimerism 781
WBC count 2233
Whole-blood donors 890, 895
Whole-blood plasma, leukodepleted 460
Whole-blood storage 2038, 2050
Whole-blood units, sickle trait 2233
Wound healing 672

X

X-chromosome genotypes 1276
X-chromosome haplotypes 1050
XK gene product 299
X-linked STRs 1050
XT 2000i 1651

Y

Y-chromosome STRs 918
Yield
  CD34+ cells 824
  RBCs 2297
  WBC 1042
Y-lineage transmission 918

Z

ZENA 1621